Welcome to the first lesson in our module on the diagnosis and management of acromegaly. In our previous lessons, we built a comprehensive clinical picture of this condition, examining its characteristic physical manifestations and the serious systemic complications that drive its morbidity and mortality. With this foundation, you can now recognize the signs and symptoms that should raise suspicion of acromegaly.
This lesson will transition from clinical suspicion to definitive diagnosis. We will systematically outline the modern, consensus-based diagnostic pathway. You will learn how to biochemically screen for, confirm, and then anatomically localize the source of growth hormone excess. Our focus will remain theoretical, centered on the evidence and guidelines that underpin this process, perfectly aligning with your preference for understanding the 'why' behind the 'how'. By the end of this lesson, you will be able to outline the diagnostic sequence for acromegaly, from initial screening with IGF-1 to confirmation with OGTT and localization with MRI.
The Diagnostic Algorithm: From Suspicion to Confirmation
The diagnostic journey in acromegaly begins with clinical suspicion. The physical changes and comorbidities we have discussed are the triggers for investigation. Given the insidious onset of the disease, this suspicion might arise from observing long-term changes in a patient's appearance or when investigating comorbidities like sleep apnea, hypertension, or difficult-to-control diabetes.
Once acromegaly is suspected, we embark on a structured, stepwise evaluation. The flowchart below provides a high-level overview of this pathway, which we will dissect in detail throughout this lesson.
This process involves three core steps:
- Biochemical Screening: To detect evidence of GH excess.
- Biochemical Confirmation: To definitively establish autonomous GH secretion.
- Anatomical Localization: To identify the source of the excess GH, which is most often a pituitary adenoma.
The image below offers a more detailed perspective, integrating clinical features with the diagnostic and therapeutic timeline. Note the section on the "Evolution of biochemical criteria," which highlights that our diagnostic standards have been refined over time as assay technology and clinical evidence have advanced. We will be focusing on the most current criteria.
Step 1: Initial Screening — The Role of IGF-1
The first and most important biochemical test in a patient with suspected acromegaly is the measurement of serum insulin-like growth factor 1 (IGF-1). You might wonder why we don't measure growth hormone (GH) directly. The following video provides a concise explanation.
Gigantism & Acromegaly | Growth Hormone, Signs & Symptoms, Diagnosis, Treatment
This clip from JJ Medicine clearly explains why IGF-1 is the preferred initial test over random GH.
Please watch the segment from the discussion on IGF-1. The key takeaway is the difference in secretion patterns between GH and IGF-1.
As the video explains, GH is released from the pituitary in a pulsatile manner, meaning its levels can fluctuate dramatically throughout the day. A single random GH measurement could be misleadingly low even in a patient with acromegaly. In contrast, IGF-1 is produced primarily by the liver under stimulation from GH and has a much longer half-life, resulting in stable, non-pulsatile serum concentrations. Therefore, an IGF-1 level provides a reliable, integrated assessment of total GH secretion over the preceding 24 hours.
The most recent international consensus provides a clear, specific criterion for using IGF-1 to diagnose acromegaly.
[PDF] Consensus on criteria for acromegaly diagnosis and remission - Pure
This 2023 consensus statement from leading experts defines the current gold standard for diagnosis. This section details the primary diagnostic role of IGF-1.
Please read the subsection titled "IGF-I and GH assays." Focus on the specific threshold for IGF-1 that confirms the diagnosis, as stated in the first paragraph of this subsection.
The key diagnostic criterion is an IGF-1 level greater than 1.3 times the upper limit of the normal range for the patient's age. It is crucial that the measurement is performed using a well-validated assay with robust, age-stratified reference data.
However, interpreting IGF-1 levels requires clinical nuance, as several conditions can influence its concentration.
A Comprehensive Review of Four Clinical Practice Guidelines of Acromegaly - PMC
This review article provides a practical discussion on the interpretation of biochemical tests for acromegaly.
Please read the portion of the "Diagnosis" section that discusses confounding factors. Start from the paragraph beginning with "Nevertheless" and review the list of conditions that can affect IGF-1 and GH levels in the accompanying Table 1.
As the reading highlights, conditions such as malnutrition, chronic liver or kidney disease, and the use of oral estrogens can lead to states of "GH resistance," where GH levels might be high but IGF-1 levels are paradoxically low or normal. Conversely, pregnancy and puberty are associated with physiologically high IGF-1 levels. These factors must be considered when interpreting results.
Step 2: Confirmation — The Oral Glucose Tolerance Test (OGTT)
If the initial IGF-1 level is unequivocally elevated (e.g., >1.3x ULN) in a patient with classic clinical features, the diagnosis is essentially confirmed. However, in cases where the IGF-1 level is borderline or equivocal, a confirmatory test is required to demonstrate the autonomous, non-suppressible nature of GH secretion. The gold standard for this is the oral glucose tolerance test (OGTT).
The principle behind the OGTT is based on normal physiology: in a healthy person, a glucose load (hyperglycemia) suppresses GH secretion from the pituitary. In patients with acromegaly, the pituitary adenoma secretes GH autonomously, so this normal suppressive feedback mechanism is lost.
[PDF] Consensus on criteria for acromegaly diagnosis and remission - Pure
Returning to the 2023 consensus statement, this section details the modern role and methodology of the OGTT.
First, in the "Diagnostic assessment" section near the beginning of the article, review the sentence that clarifies when an OGTT is useful: for equivocal results. Next, please read the entire subsection titled "OGTT". Pay close attention to: The consensus recommendation on when to reserve this test. The procedure (75g glucose load with timed GH measurements). The concept of a paradoxical GH rise, which can occur in some patients with acromegaly.
To summarize the key points from this reading:
- Indication: The OGTT is no longer considered mandatory for all patients. It is reserved for cases with equivocal IGF-1 results.
- Procedure: A 75g oral glucose load is administered after an overnight fast, with serum GH measured at baseline and at 30, 60, 90, and 120 minutes.
- Interpretation: A diagnosis of acromegaly is confirmed if the GH level fails to suppress to a pre-defined nadir (lowest point). Historically, this cutoff was <1 µg/L, but with modern ultrasensitive assays, lower cutoffs are sometimes used. A paradoxical increase in GH after the glucose load is also highly suggestive of acromegaly.
Step 3: Localization — Pituitary MRI
Once the biochemical diagnosis of acromegaly is secure, the final step is to identify the source of GH hypersecretion. Over 95% of cases are caused by a GH-secreting pituitary adenoma. Therefore, the imaging modality of choice is a magnetic resonance imaging (MRI) scan of the pituitary gland.
[PDF] Consensus on criteria for acromegaly diagnosis and remission - Pure
This section of the consensus paper outlines the best practices for imaging in acromegaly.
Please read the entire subsection titled "Imaging". Note the specific recommendations for the type of MRI and the information that should be included in the radiology report.
The standard is a gadolinium-enhanced pituitary MRI, preferably performed on a high-field (1.5T or 3T) scanner with thin slices. This provides the necessary resolution to identify the adenoma, which is often a microadenoma (<1 cm) at the time of diagnosis. The MRI is crucial not only for confirming the presence and size of the adenoma but also for surgical planning, as it shows the tumor's relationship to surrounding structures like the optic chiasm and cavernous sinuses.
In the rare event that a pituitary MRI is normal or shows only diffuse enlargement (hyperplasia), the diagnostic algorithm directs us to consider an extrapituitary source of GH excess. This typically involves searching for a neuroendocrine tumor (e.g., in the lung or pancreas) that is ectopically secreting either GH or, more commonly, GH-releasing hormone (GHRH). This search usually involves CT scans of the chest and abdomen and measurement of plasma GHRH.
Conclusion
In this lesson, we have constructed the modern, evidence-based diagnostic pathway for acromegaly. You are now equipped with the theoretical framework to move from clinical suspicion to a definitive diagnosis.
Key Takeaways:
- The diagnostic process is a three-step sequence: screening, confirmation, and localization.
- The primary screening test is a measurement of serum IGF-1, which should be interpreted using age-specific reference ranges. An IGF-1 level >1.3x the upper limit of normal is highly suggestive of acromegaly.
- The confirmatory test, reserved for equivocal cases, is the oral glucose tolerance test (OGTT). A failure of GH to suppress after a 75g glucose load confirms autonomous GH secretion.
- Once acromegaly is biochemically confirmed, a gadolinium-enhanced pituitary MRI is performed to localize the causative pituitary adenoma.
- In the rare case of a normal pituitary MRI, an investigation for an ectopic GHRH- or GH-secreting tumor is warranted.
Having established how to diagnose acromegaly, our next lesson will turn to the principles of its management. We will begin by defining the goals of treatment and then explore the role of transsphenoidal surgery, which stands as the first-line therapy for the majority of patients.